TIDMDPH
RNS Number : 8263P
Dechra Pharmaceuticals PLC
21 October 2021
Thursday, 21 October 2021
Dechra(R) Pharmaceuticals PLC
Results of Annual General Meeting (AGM)
A poll was held on each of the resolutions proposed at the
Annual General Meeting (AGM) of the Company held today
(21 October 2021). All resolutions were passed and are as
follows:
Resolution (No. Total For (includes Total Against Total Cast Withheld
as noted on proxy Discretionary) (excludes Withheld) (1)
form)
No. of votes % of No. of % of No. of % of No. of
vote votes vote votes vote votes
------------- ------- ---------- ------ -------------- ------- ----------
Ordinary Business:
------------- ------- ---------- ------ -------------- ------- ----------
Resolution 1:
To receive the
accounts, the
Strategic Report,
the Directors'
Report and the
Auditor's Report 79,448,606 99.82% 143,377 0.18% 79,591,983 73.48 663,610
------------- ------- ------ ------- ----------
Resolution 2:
To approve the
Directors' Remuneration
Report 73,810,257 92.98% 5,568,679 7.02% 79,378,936 73.28 876,657
------------- ------- ------ ------- ----------
Resolution 3:
To declare a final
dividend 80,166,277 99.89% 89,166 0.11% 80,255,443 74.09 150
------------- ------- ------ ------- ----------
Resolution 4:
To elect Denise
Goode 79,625,037 99.22% 627,942 0.78% 80,252,979 74.09 2,614
------------- ------- ------ ------- ----------
Resolution 5:
To re-elect William
Anthony Rice 74,049,166 93.28% 5,335,791 6.72% 79,384,957 73.29 870,636
------------- ------- ------ ------- ----------
Resolution 6:
To re-elect Ian
Page 79,100,749 99.25% 600,742 0.75% 79,701,491 73.58 554,102
------------- ------- ------ ------- ----------
Resolution 7:
To re-elect Anthony
Griffin 79,676,525 99.28% 575,456 0.72% 80,251,981 74.09 3,612
------------- ------- ------ ------- ----------
Resolution 8:
To re-elect Paul
Sandland 79,610,115 99.20% 641,866 0.80% 80,251,981 74.09 3,612
------------- ------- ------ ------- ----------
Resolution 9:
To re-elect Lisa
Bright 78,905,240 98.32% 1,347,739 1.68% 80,252,979 74.09 2,614
------------- ------- ------ ------- ----------
Resolution 10:
To re-elect Julian
Heslop 78,904,870 98.32% 1,345,590 1.68% 80,250,460 74.09 5,133
------------- ------- ------ ------- ----------
Resolution 11:
To re-elect Ishbel
Macpherson 76,155,668 94.89% 4,097,310 5.11% 80,252,978 74.09 2,615
------------- ------- ------ ------- ----------
Resolution 12:
To re-elect Lawson
Macartney 78,909,123 98.33% 1,342,858 1.67% 80,251,981 74.09 3,612
------------- ------- ------ ------- ----------
Resolution 13:
To re-elect Alison
Platt 78,904,047 98.32% 1,348,932 1.68% 80,252,979 74.09 2,614
------------- ------- ------ ------- ----------
Resolution 14:
To re-appoint
PricewaterhouseCoopers
as external auditor
of the company 79,641,188 99.24% 611,253 0.76% 80,252,441 74.09 3,152
------------- ------- ------ ------- ----------
Resolution 15:
To authorise the
Audit Committee
to determine the
remuneration of
the external auditor 80,202,414 99.94% 49,995 0.06% 80,252,409 74.09 3,184
------------- ------- ------ ------- ----------
Special Business:
------------- ------- ------ ------- ----------
Resolution 16:
To authorise the
directors to allot
shares to specific
limits 76,333,783 95.12% 3,919,660 4.88% 80,253,443 74.09 2,150
------------- ------- ------ ------- ----------
Resolution 17:
To disapply the
pre-emption rights 80,204,580 99.94% 45,655 0.06% 80,250,235 74.09 5,358
------------- ------- ------ ------- ----------
Resolution 18:
To disapply additional
pre-emption rights 78,534,264 97.86% 1,718,271 2.14% 80,252,535 74.09 3,058
------------- ------- ------ ------- ----------
Resolution 19:
To authorise the
Company to purchase
its own shares 79,403,128 98.98% 818,816 1.02% 80,221,944 74.06 33,649
------------- ------- ------ ------- ----------
Resolution 20:
To authorise the
Company to hold
any general meeting
(other than an
AGM) on not less
than 14 clear
days' notice 76,073,415 96.53% 2,734,994 3.47% 78,808,409 72.76 1,447,184
------------- ------- ------ ------- ----------
Resolution 21:
To approve the
Rules of the Dechra
2021 Deferred
Bonus Plan 76,194,020 95.60% 3,507,352 4.40% 79,701,372 73.58 554,221
------------- ------- ------ ------- ----------
Notes:
1. A "vote withheld" is not a vote in law and is not counted in
the calculation of the proportion of votes "For" and "Against" a
resolution.
2. Resolutions 1 to 16 and Resolution 21 were ordinary
resolutions, requiring more than 50% of shareholder votes to be
"For" the resolutions.
3. Resolutions 17 to 20 were special resolutions, requiring more
than 75% of shareholder votes to be "For" the resolutions.
4. Issued Share Capital at meeting date: 108,319,960.
5. Equiniti, Registrar to the Company, were appointed for the
purpose of the Poll taken at the AGM and certify as scrutineer that
the result of the Poll is correctly set out above.
In accordance with Listing Rule 9.6.2R, a copy of the
resolutions passed as special business at the AGM have been
submitted to the National Storage Mechanism and will shortly be
available for inspection at the FCA document viewing facility
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
For further information, please contact:
Melanie Hall
Company Secretary
Dechra Pharmaceuticals PLC
Telephone: +44 (0) 1606 814 730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, marketing and sales of high quality products
exclusively for veterinarians worldwide. The majority of Dechra's
products are focused on key therapeutic categories where we have
leading market positions, and many of our products are used to
treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor
products. For more information, please visit: www.dechra.com .
Trademarks
Trademarks appear throughout this document in italics. Dechra
and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGFEMSUFEFSELS
(END) Dow Jones Newswires
October 21, 2021 05:49 ET (09:49 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
